• DILIsym_Process_DSS_promo

    BioWorld Article 

     

    DILIsym and DILI-sim Initiative Highlighted at Digestive Disease Week (DDW) 2017

     

    LEARN MORE

  • Highlighted Liver-560x310

    Simulations Plus to Acquire DILIsym Services, Inc.  

    Accretive acquisition to expand Simulations Plus offerings by adding leading provider of drug-induced liver injury (DILI) software and consulting services


    LEARN MORE

  • DILIsym web promo

    DILIsym Services, Inc. Evaluates Prospective NAFLD Treatment, Utilizing Its Flagship Technology in Collaboration with Pfizer, Inc.

    Companies presented preliminary results at ASCPT in Washington, D.C.  

     

    LEARN MORE

DILIsym®: An In Silico Model of Drug-Induced Liver Injury 

DILIsym® is a “middle-out”, multi scale computational model of drug-induced liver injury (DILI). The software is designed to be used during drug development to provide an enhanced understanding of the DILI hazard posed by individual molecules and to provide deeper insight into the mechanisms responsible for observed DILI responses at various stages of the development process.

Dr. Paul WatkinsThe DILI-sim Initiative is a consortium of life science companies led by DILIsym Services, Inc. and charged with developing the DILIsym® software. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs.

The Initiative is led by Dr. Paul B. Watkins, Director of the University of North Carolina Institute for Drug Safety Sciences, located in the heart of Research Triangle Park, North Carolina. 

Companies Supporting DILIsym® Software Development

2016 04 DILIsim Consortium 2